Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824536 · ClinicalTrials.gov registry record · Phase 1
3BNC117 and 10-1074 in HIV Uninfected Adults
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02824536 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 24 participants.
The verdict
NCT02824536, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a phase 1 clinical trial to evaluate the safety and pharmacokinetics of the highly neutralizing anti-human immunodeficiency virus-1 monoclonal antibodies 3BNC117 and 10-1074, when given in combination, in human immunodeficiency virus (HIV)-uninfected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use as prophylaxis against HIV infection in healthy HIV-uninfected individuals at risk for HIV infection.
Interventions
- DRUG Placebo
- DRUG 3BNC117
- DRUG 10-1074
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-06-23 |
| Est. Completion | 2018-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02824536
The ClinicalTrials.gov registry entry for NCT02824536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02824536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02824536 about?
NCT02824536 is a clinical study titled "3BNC117 and 10-1074 in HIV Uninfected Adults". This is a phase 1 clinical trial to evaluate the safety and pharmacokinetics of the highly neutralizing anti-human immunodeficiency virus-1 monoclonal antibodies 3BNC117 and 10-1074, when given in combination, in human immunodeficiency virus (HIV)-uninfected individuals. This study is intended to su...
What is the current status of trial NCT02824536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-06-23. Estimated completion is 2018-01-09.
What interventions are being tested in trial NCT02824536?
The interventions under investigation include: Placebo (DRUG), 3BNC117 (DRUG), 10-1074 (DRUG).
Who is sponsoring clinical trial NCT02824536?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.